Home Science & Medicine Immunotherapy

Immunotherapy

Feature articles about current research in immunology that has significant impact or impact potential on thoracic oncology.

Exploring the Potential of Immuno-oncology Combination Therapy

By Cynthia L. Kryder, MS, CCC-Sp Editor Note: The article is part of a newly launched ongoing series about immunooncology (IO) combination therapy, future articles...

AACR 2018: First-Line Management of Advanced NSCLC Enters New Era

By Corey Langer, MD, IASLC Lung Cancer News Editor The therapeutic landscape irrevocably altered on April 17, 2018, when three pivotal trials—KEYNOTE 189, CheckMate 227...

PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays

By Fred R. Hirsch, MD, PhD Immunotherapy is a very encouraging development in the treatment of patients with lung cancer. At this phase of its refinement,...

Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to...

By Ross Soo, MB BS, PhD, FRACP The treatment of patients with advanced NSCLC harbouring an actionable oncogene with tyrosine kinase inhibitors (TKIs) directed at...

Update on Checkpoint Inhibitors in Lung Cancer

By Erik J. MacLaren, PhD The growing number of checkpoint inhibitors currently being developed, without question, has ushered in a new era in clinical oncology,...

The CRISPR-Cas9 Toolkit: Moving From Bench to Bedside

By Cynthia L. Kryder, MS Decades of immunology research have shown that it is possible to harness the power of the immune system to fight...

PACIFIC Trial Leads to Durvalumab Approval in United States

The U.S. Food and Drug Administration approved durvalumab on February 16, 2018, for the treatment of patients with stage III NSCLC whose tumors are...

Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou

In the following interview, Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of Thoracic Medical Oncology at...

KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease

By Kara Nyberg, PhD The pace of research focused on new therapies for advanced NSCLC has progressed from a trot to a sprint in recent...

PD-L1 Blueprint Project

By Fred R. Hirsch, MD, PhD In the new era of immunotherapy in thoracic cancer, evaluating PD-L1 status remains a clinical challenge. In recognition of...

Meeting News